Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rogier C Buijsman

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Drug Discovery Today|June 1, 2005
Synthetic heparin derivatives as new anticoagulant drugsMartin de Kort, Rogier C Buijsman, Constant A A van Boeckel
Current Medicinal Chemistry|May 17, 2005
Non-steroidal steroid receptor modulatorsRogier C Buijsman, Pedro H H Hermkens, Rachel D van Rijn, et al.
British Journal of Pharmacology|January 19, 2012
A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targetsJoost C M Uitdehaag, Folkert Verkaar, Husam Alwan, et al.
Journal of Biomolecular Screening|May 30, 2014
High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymesNicole Seegers, Antoon M van Doornmalen, Joost C M Uitdehaag, et al.
Journal of Structural Biology: X|July 11, 2020
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158Yvonne Grobben, Joost C M Uitdehaag, Nicole Willemsen-Seegers, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 19, 2020
High-Throughput Fluorescence-Based Activity Assay for Arginase-1Yvonne Grobben, Nicole Willemsen-Seegers, Joost C M Uitdehaag, et al.
Molecular Cancer Therapeutics|July 29, 2017
TTK Inhibitors as a Targeted Therapy for <i>CTNNB1</i> (<b>β</b>-catenin) Mutant CancersGuido J R Zaman, Jeroen A D M de Roos, Marion A A Libouban, et al.
Journal of Molecular Biology|January 4, 2017
Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon ResonanceNicole Willemsen-Seegers, Joost C M Uitdehaag, Martine B W Prinsen, et al.
Angewandte Chemie (International Ed. in English)|April 12, 2017
Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-SpineHeike K Wentsch, Niklas M Walter, Mike Bührmann, et al.
Neuro-Oncology Advances|July 17, 2023
Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategiesMegan Houweling, Anna Giczewska, Kulsoom Abdul, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Drug Discovery Today|June 1, 2005
Synthetic heparin derivatives as new anticoagulant drugsMartin de Kort, Rogier C Buijsman, Constant A A van Boeckel
Current Medicinal Chemistry|May 17, 2005
Non-steroidal steroid receptor modulatorsRogier C Buijsman, Pedro H H Hermkens, Rachel D van Rijn, et al.
British Journal of Pharmacology|January 19, 2012
A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targetsJoost C M Uitdehaag, Folkert Verkaar, Husam Alwan, et al.
Journal of Biomolecular Screening|May 30, 2014
High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymesNicole Seegers, Antoon M van Doornmalen, Joost C M Uitdehaag, et al.
Journal of Structural Biology: X|July 11, 2020
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158Yvonne Grobben, Joost C M Uitdehaag, Nicole Willemsen-Seegers, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 19, 2020
High-Throughput Fluorescence-Based Activity Assay for Arginase-1Yvonne Grobben, Nicole Willemsen-Seegers, Joost C M Uitdehaag, et al.
Molecular Cancer Therapeutics|July 29, 2017
TTK Inhibitors as a Targeted Therapy for <i>CTNNB1</i> (<b>β</b>-catenin) Mutant CancersGuido J R Zaman, Jeroen A D M de Roos, Marion A A Libouban, et al.
Journal of Molecular Biology|January 4, 2017
Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon ResonanceNicole Willemsen-Seegers, Joost C M Uitdehaag, Martine B W Prinsen, et al.
Angewandte Chemie (International Ed. in English)|April 12, 2017
Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-SpineHeike K Wentsch, Niklas M Walter, Mike Bührmann, et al.
Neuro-Oncology Advances|July 17, 2023
Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategiesMegan Houweling, Anna Giczewska, Kulsoom Abdul, et al.
Pageof 3